Stockholders Partially Settle Bioverativ Suit In Del. For $84M
Stockholders of biotech venture Bioverativ Inc. have settled for $84 million a Delaware Court of Chancery class challenge to the company's sale to Sanofi Inc. in 2018, releasing most directors and...To view the full article, register now.
Already a subscriber? Click here to view full article